Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-03-2000 | Oral presentation

Clinical trials in breast cancer; do we have the right approaches?

Author: PE Lønning

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

While adjuvant chemotherapy as well as hormone therapy improve long-term survival in breast cancer patients [1, 2], only about 25-30% of patients at risk are cured by such treatment modalities. While improved regimens using more effective chemotherapeutics have been shown to improve outcome marginally [3], the disappointing results from high-dose chemotherapy with stem cell support [4, 5] underlines the limitations associated with current chemotherapy. …
Literature
1.
2.
Clarke M, et al: . Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.CrossRef
3.
4.
Peters W, et al: . Proc Am Soc Clin Oncol. 1999, 18: 1a. (Abstr, 2, p1.a)-
5.
Scandinavian Breast Cancer Group Study. Proc Am Soc Clin Oncol . 1999, 18: 2a. (Abstr, 3, p2.a)-
6.
7.
8.
9.
Kandioler-Eckerberger D, et al: . Proc Am Soc Clin Oncol . 1998, 17: 102a. (Abstr, 392)-
Metadata
Title
Clinical trials in breast cancer; do we have the right approaches?
Author
PE Lønning
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr193

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Meeting abstract

Promising method for DNA extraction from paraffin embedded archive material

Meeting abstract

Screening for BRCA1 gene mutations by capillary electrophoretic REF-SSCP

Oral presentation

The pathology of inherited breast tumours

Oral presentation

Clinical translation of progress in molecular endocrinology

Meeting abstract

Embryonic lethality in the Brca1-1700T mouse model suggests inhibition of p53-dependent pathways

Meeting abstract

Role of the breast cancer susceptibility gene BRCA1 in radio-resistance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits